Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$122.54M-$131.12M
$2.16M-28.6%$2.4M-27.1%$2.61M$2.83M$3.03M
$20.28M+92.0%$16.4M+70.0%$13.18M$11.66M$10.56M
-$121.54M-$111.94M
$588K-49.6%$794K-30.8%$1.37M$1.4M$1.17M
-$164.39M-13,986%-$170.96M-14,805%-$68.18M-$1.4M-$1.17M
$190.32M-3.8%$275.34M+190%$342.01M$198.25M$197.79M
-$95.61M-$7.57M$167.17M
-$122.13M-$112.73M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Maze Therapeutics, Inc. Common Stock generate?
Maze Therapeutics, Inc. Common Stock (MAZE) generated -$121.5M in operating cash flow over the trailing twelve months.
What is Maze Therapeutics, Inc. Common Stock's free cash flow?
After $588.0K of capital expenditures, Maze Therapeutics, Inc. Common Stock's free cash flow was -$122.1M over the trailing twelve months.
Where does Maze Therapeutics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.